BioSpace News Archive

Olatec Therapeutics LLC (Olatec) today announced the first publication from its preclinical studies with dapansutrile in selected cancer models. The data in this paper, entitled “Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion”, is published in the Proceedings of the National Academy of Sciences (PNAS).

Quantum Leap Healthcare Collaborative (QLHC), the sponsor of the I-SPY COVID Trial, today announced that cenicriviroc (CVC) has been dropped from the trial due to futility, based on the low likelihood of success.

Seven and Eight Biopharmaceuticals Inc., a clinical stage biotechnology company focused on developing proprietary novel immuno-oncology therapies to activate the immune system against cancer, today announced the acceptance of an abstract for a poster discussion presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.

Superior performance with smaller training datasets holds potential for rare diseases and other clinical applications where training data is limited

ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that two abstracts highlighting preliminary results from the Phase 1b study of ORIC-101 in combination with nab-paclitaxel have been accepted for poster presentations during the 2021 American Society of Clinical Oncology Annual Meeting, to be held June 4 - 8, 2021.

Company to Hold Webcast to Review Data from Ongoing SRF388 and SRF617 Phase 1 Clinical Studies on Friday, June 4th at 8:00 a.m. ET

Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates targeting cancers in areas of high unmet medical need, announced the grant of an inducement award to the newly appointed Senior Vice President and Chief Legal Officer, Alejandra Carvajal.

Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), announced today that Laurence J.N. Cooper, PhD, MD, Scientific Advisor to the Company, was the inaugural presenter at Aldevron’s Virtual Breakthrough Speaker Series.

Histogen Inc., a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, announced that Histogen’s financial results for the second quarter will be released after the close of market on Thursday, May 13, 2021.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil Kakkis, M.D., Ph.D., will present at the 7th Annual Truist Securities Life Sciences Summit on Wednesday, May 5, 2021 at 1:00 PM ET.